Giulia Valdiserra

720 total citations · 1 hit paper
21 papers, 425 citations indexed

About

Giulia Valdiserra is a scholar working on Infectious Diseases, Rheumatology and Neurology. According to data from OpenAlex, Giulia Valdiserra has authored 21 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 5 papers in Rheumatology and 4 papers in Neurology. Recurrent topics in Giulia Valdiserra's work include SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Giulia Valdiserra is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (7 papers), COVID-19 Clinical Research Studies (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Giulia Valdiserra collaborates with scholars based in Italy, United States and Sweden. Giulia Valdiserra's co-authors include Emiliano Cappello, Marco Tuccori, Daniele Focosi, Irma Convertino, Sara Ferraro, Corrado Blandizzi, Scott A. McConnell, Arturo Casadevall, Fabrizio Maggi and Ugo Moretti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and The Lancet Infectious Diseases.

In The Last Decade

Giulia Valdiserra

20 papers receiving 418 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Monoclonal antibody therapies against SARS-CoV-2

2022 156 citations Daniele Focosi, Scott A. McConnell et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giulia Valdiserra Italy	7	305	76	52	51	46	21	425
Emiliano Cappello Italy	8	305 1.0×	93 1.2×	53 1.0×	51 1.0×	50 1.1×	22	466
Sara Ferraro Italy	10	185 0.6×	53 0.7×	28 0.5×	30 0.6×	41 0.9×	29	358
Yen-Der Li United States	9	285 0.9×	174 2.3×	27 0.5×	27 0.5×	65 1.4×	10	548
F. Akter Bangladesh	4	404 1.3×	98 1.3×	34 0.7×	61 1.2×	28 0.6×	5	553
Alejandra Barreto Ecuador	5	416 1.4×	113 1.5×	24 0.5×	51 1.0×	86 1.9×	7	571
Xihua Lian China	7	293 1.0×	123 1.6×	38 0.7×	56 1.1×	30 0.7×	18	553
Martin Lier Germany	5	533 1.7×	134 1.8×	38 0.7×	54 1.1×	66 1.4×	8	607
Yetian Dong China	4	366 1.2×	105 1.4×	26 0.5×	44 0.9×	62 1.3×	7	442
Ali Ardakani Canada	5	256 0.8×	81 1.1×	24 0.5×	19 0.4×	26 0.6×	6	332
Shih-Hwa Chiou Taiwan	5	399 1.3×	195 2.6×	37 0.7×	98 1.9×	41 0.9×	11	683

Countries citing papers authored by Giulia Valdiserra

Since Specialization

Citations

This map shows the geographic impact of Giulia Valdiserra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Valdiserra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Valdiserra more than expected).

Fields of papers citing papers by Giulia Valdiserra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Valdiserra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Valdiserra. The network helps show where Giulia Valdiserra may publish in the future.

Co-authorship network of co-authors of Giulia Valdiserra

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Valdiserra. A scholar is included among the top collaborators of Giulia Valdiserra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Valdiserra. Giulia Valdiserra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lucarini, Elena, Laura Benvenuti, Vanessa D’Antongiovanni, et al.. (2024). Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study. Frontiers in Pharmacology. 15. 1466824–1466824. 1 indexed citations

D’Antongiovanni, Vanessa, Laura Benvenuti, Matteo Fornai, et al.. (2024). The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis. Journal of drug targeting. 32(8). 953–963. 3 indexed citations

Sciancalepore, Francesco, Niccolò Lombardi, Giulia Valdiserra, et al.. (2024). Prevalence, Incidence, and Mortality of Myasthenia Gravis and Myasthenic Syndromes: A Systematic Review. Neuroepidemiology. 59(5). 579–592. 4 indexed citations

Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2023). Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy. Frontiers in Pharmacology. 14. 1244486–1244486.

Convertino, Irma, Valentina Lorenzoni, Rosa Gini, et al.. (2023). Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis. Pharmaceuticals. 16(3). 465–465. 1 indexed citations

Valdiserra, Giulia, Nadia Mores, Laura Sottosanti, et al.. (2023). Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation. SHILAP Revista de lepidopterología. 3. 1194683–1194683. 2 indexed citations

Convertino, Irma, et al.. (2023). Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert Opinion on Drug Discovery. 18(3). 231–245. 4 indexed citations

Ferraro, Sara, et al.. (2023). Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option. Expert Opinion on Drug Discovery. 19(1). 9–20. 7 indexed citations

Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2022). Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert Opinion on Drug Discovery. 17(6). 531–546. 4 indexed citations

10.

Franchini, Massimo, Emiliano Cappello, Giulia Valdiserra, et al.. (2022). Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review. Seminars in Thrombosis and Hemostasis. 49(1). 15–26. 12 indexed citations

11.

Focosi, Daniele, Scott A. McConnell, Arturo Casadevall, et al.. (2022). Monoclonal antibody therapies against SARS-CoV-2. The Lancet Infectious Diseases. 22(11). e311–e326. 156 indexed citations breakdown →

12.

Crescioli, Giada, Silvia Cascini, Emiliano Cappello, et al.. (2022). Riluzole use in presence of contraindications in adults affected by amyotrophic lateral sclerosis and its off-label use in other motor neuron diseases: Findings from an Italian multicentre study (the CAESAR project). SHILAP Revista de lepidopterología. 2. 3 indexed citations

13.

Convertino, Irma, Rosa Gini, Massimiliano Cazzato, et al.. (2021). Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study. Journal of Clinical Medicine. 10(24). 5743–5743. 3 indexed citations

14.

Tuccori, Marco, Rosa Gini, Giuseppe Turchetti, et al.. (2021). Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study. CINECA IRIS Institutial research information system (University of Pisa). 1 indexed citations

15.

Convertino, Irma, Massimiliano Cazzato, Rosa Gini, et al.. (2021). Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases. Scientific Reports. 11(1). 20314–20314. 4 indexed citations

16.

Convertino, Irma, Marco Tuccori, Sara Ferraro, et al.. (2020). Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 24(1). 331–331. 42 indexed citations

17.

Tuccori, Marco, Irma Convertino, Sara Ferraro, et al.. (2020). The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Safety. 43(8). 699–709. 55 indexed citations

18.

Sottosanti, Laura, et al.. (2020). Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward. Drug Safety. 43(9). 853–866. 5 indexed citations

19.

Ferraro, Sara, Marco Tuccori, Irma Convertino, et al.. (2020). Olfactory and gustatory impairments in COVID‐19 patients: Role in early diagnosis and interferences by concomitant drugs. British Journal of Clinical Pharmacology. 87(5). 2186–2188. 3 indexed citations

20.

Tuccori, Marco, Sara Ferraro, Irma Convertino, et al.. (2020). Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. mAbs. 12(1). 1854149–1854149. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact